The Board of Directors

Pharmagest Group’s Board of Directors ensures the application of the principles of good governance based on a respect of ethical business practices and transparency as well as the interests of the company, its shareholders and stakeholders.

The Board’s work, which brings together a range of expertise and complementary experience, is focused on strategic issues, and in particular, increasing the company’s value.

The Board remains informed throughout the year of the Group’s business activity and results, market trends and expectations of patients and healthcare professionals throughout Europe. It studies acquisition projects and monitors the integration of recently acquired businesses.

The Directors regularly meet with the Group’s key executives. This transparent and construc-tive dialogue provides the basis for shared strategic vision that executive management is in consequence able to implement with confidence.

The Combined General Meeting of Pharmagest Group held on 29 June 2020 voted to expand the Board of Directors’ membership and approved the appointment of Grégoire de ROTALIER as Director.

Mr. de ROTALIER’s appointment increases the number of directors serving on the Board of Directors of Pharmagest Group to 12 members (with the percentage of women serving on the Board remaining in compliance with the provisions of Article L. 225-18-1 French commercial code at 41.6%).

The Audit Committee

The Audit Committee is a standing committee established by the Board of Directors to work with it on its business.

As a permanent body, the Audit Committee’s main mission is to monitor the preparation of accounting and financial information and the efficacy of the Group’s internal control and risk management systems. It is also responsible for overseeing the audit of the annual and consolidated financial statements by the Statutory Auditors and monitoring their independence.

In 2020, the Audit Committee has three members, all appointed by the Board of Directors: Ms. Marie-Louise LIGER (Independent Director), Mr. Daniel ANTOINE (Director) and Mr. François JACQUEL (Director). Based on the recommendations of the Middlenext “Corporate Governance Code”, no member of the Audit Committee exercises executive functions.

This Committee is chaired by Ms. Marie-Louise LIGER based on her specific expertise in the area of accounting and finance.

Composition of the Board of Directors as at 30.12.2020

Last Name and First Name
or Company Name of Member and their functions
Mandate expiry date
Mr Thierry CHAPUSOT
Chairman of the Board of Directors
Experience
31 december 2025
Mr Dominique PAUTRAT
CEO and Director
Experience
31 december 2025 (DG)
31 december 2020 (Adm.)
Mr Denis SUPPLISSON
Deputy CEO and Director
Experience
31 december 2025 (DG)
31 december 2020 (Adm.)
Mr Grégoire de ROTALIER
Deputy CEO and Director
Experience
31 december 2025 (DG)
31 december 2025 (Adm.)
Mr Daniel ANTOINE
Director
Experience
31 december 2025
Mrs Marie-Louise LIGER
Independant Director
Experience
31 december 2020
La Coopérative WELCOOP represented by Mr Hugues MOREAUX
Director
Experience
31 december 2025
Mr François JACQUEL
Director
Experience
31 december 2025
Mrs Anne LHOTE
Director
Experience
31 december 2022
Mrs Sophie MAYEUX
Independant Director
Experience
31 december 2023
Mrs Céline GRIS
Independant Director
Experience
31 december 2022
Mrs Emilie LECOMTE
Director
Experience
31 december 2022

Name and adresses of the auditors

SA BATT AUDIT
58, Boulevard d’Austrasie
54000 NANCY
Represented by Mrs Isabelle SAGOT since 2018
Renewed on 29 June 2020 until the General Meeting ratifying the financial statements for the year ended 31 December 2025.

DELOITTE & ASSOCIES
185C, avenue Charles de Gaulle
92200 NEUILLY-SUR-SEINE
Represented by Mr Loïc MULLER since 2019
Appointed on 27 June 2017 until the General Meeting ratifying the financial statements for the year ended 31 December 2022.

Société REVILEC AUDIT ET ASSOCIES
58, Boulevard d’Austrasie
54000 NANCY
The General Meeting of June 29, 2020 decided to not renew the appointment of the Alternate Statutory Auditors of the company REVILEC AUDIT & ASSOCIES and not to appoint a replacement in application of provisions of Article L. 823-1 of the French Commercial Code.